UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of
1934
Date of
Report (Date of earliest event reported): February 5,
2021
AMERICAN BIO MEDICA
CORPORATION
(Exact
name of registrant as specified in its charter)
New
York
|
0-28666
|
14-1702188
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification Number)
|
122
Smith Road, Kinderhook, NY
|
12106
|
(Address of
principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: 518-758-8158
Not applicable
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see
General Instruction A.2.
below):
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title of each
class
|
Trading
Symbol(s)
|
Name of each
exchange on which registered
|
Common
|
ABMC
|
OTC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging
growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
ITEM 5.02.
DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF
CERTAIN OFFICERS.
Resignation of Director
On February 5, 2021, Chaim Davis notified American Bio Medica
Corporation (the "Company") that he was resigning from the
Company's Board of Directors (the "Board") effective immediately.
Mr. Davis’s decision to resign was for a personal reason, so
as to free up his time to focus on his other business commitments.
His resignation was not the result of any disagreement with the
Company or its management with respect to any matter relating to
the Company's operations, policies or practices.
Mr. Davis also served as the Chairman of the Board of Directors and
served on the Audit, Compensation and Nominating Committees of the
Board of Directors.
The Company’s remaining board members (Jean Neff, Peter
Jerome and CEO Melissa Waterhouse) will promptly begin a search for
a new independent director to fill the vacancy created by Mr.
Davis’s resignation. The role of Chairman of the Board will
remain vacant until an experienced and qualified successor is
identified. As provided under the Company’s Bylaws, in the
absence of the appointment of a new Chairman of the Board and until
a new Chairman is appointed, the Company’s Chief Executive
Officer, Melissa Waterhouse, will assume the responsibilities of
the Chairman of the Board.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AMERICAN BIO MEDICA
CORPORATION (Registrant)
|
|
|
|
|
|
|
Date:
February 11, 2021
|
By:
|
/s/ Melissa A.
Waterhouse
|
|
|
|
Melissa A.
Waterhouse
|
|
|
|
Chief
Executive Officer (Principal Executive Officer)
Principal Financial
Officer
|
|